NZ500936A - Retroviral vector particles produced in a baculovirus expression system capable of delivering a nucleotide sequence of interest (NOI) - Google Patents

Retroviral vector particles produced in a baculovirus expression system capable of delivering a nucleotide sequence of interest (NOI)

Info

Publication number
NZ500936A
NZ500936A NZ500936A NZ50093698A NZ500936A NZ 500936 A NZ500936 A NZ 500936A NZ 500936 A NZ500936 A NZ 500936A NZ 50093698 A NZ50093698 A NZ 50093698A NZ 500936 A NZ500936 A NZ 500936A
Authority
NZ
New Zealand
Prior art keywords
retroviral
promoter
retroviral vector
composition according
genome
Prior art date
Application number
NZ500936A
Other languages
English (en)
Inventor
Alan John Kingsman
Ian Martin Jones
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NZ500936A publication Critical patent/NZ500936A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ500936A 1997-06-04 1998-06-04 Retroviral vector particles produced in a baculovirus expression system capable of delivering a nucleotide sequence of interest (NOI) NZ500936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711578.6A GB9711578D0 (en) 1997-06-04 1997-06-04 Novel retroviral vector production systems
PCT/GB1998/001626 WO1998055640A1 (en) 1997-06-04 1998-06-04 Retroviral vector particles produced in a baculovirus expression system

Publications (1)

Publication Number Publication Date
NZ500936A true NZ500936A (en) 2001-11-30

Family

ID=10813571

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ500936A NZ500936A (en) 1997-06-04 1998-06-04 Retroviral vector particles produced in a baculovirus expression system capable of delivering a nucleotide sequence of interest (NOI)

Country Status (11)

Country Link
EP (1) EP0986649A1 (ja)
JP (1) JP2002510204A (ja)
KR (1) KR20010013332A (ja)
CN (1) CN1259171A (ja)
AU (1) AU741764B2 (ja)
CA (1) CA2289491A1 (ja)
GB (1) GB9711578D0 (ja)
IL (1) IL132359A0 (ja)
NO (1) NO995900L (ja)
NZ (1) NZ500936A (ja)
WO (1) WO1998055640A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
AU2002230545B2 (en) 2000-10-23 2006-09-21 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (HIV-2)
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2241626B1 (en) * 2008-01-09 2016-01-06 Konkuk University Industrial Cooperation Corp Baculovirus-based vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3179455B2 (ja) * 1987-07-24 2001-06-25 カイロン コーポレイション エアーリフト昆虫細胞培養
AU651311B2 (en) * 1988-03-21 1994-07-21 Chiron Corporation Recombinant retroviruses
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
GB9510272D0 (en) * 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors

Also Published As

Publication number Publication date
WO1998055640A1 (en) 1998-12-10
CA2289491A1 (en) 1998-12-10
AU7780098A (en) 1998-12-21
NO995900L (no) 2000-02-04
EP0986649A1 (en) 2000-03-22
GB9711578D0 (en) 1997-07-30
IL132359A0 (en) 2001-03-19
AU741764B2 (en) 2001-12-06
NO995900D0 (no) 1999-12-02
KR20010013332A (ko) 2001-02-26
JP2002510204A (ja) 2002-04-02
CN1259171A (zh) 2000-07-05

Similar Documents

Publication Publication Date Title
US7419829B2 (en) Vector system
JP4640742B2 (ja) 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段
EP1080216B1 (en) Retroviral delivery system
US20090111106A1 (en) Vector System
JP2001517452A (ja) 機能的スプライス・ドナー部位及び機能的スプライス・アクセプター部位を含むレトロウイルスベクター
US6818209B1 (en) Retroviral delivery system
JP2002538829A (ja) 抗ウイルスベクター
JP5484897B2 (ja) 遺伝子治療のためのベクター
JP2019514414A (ja) ゲノム工学システムのカプシド形成のための粒子
US9932597B2 (en) Vectors for transgene expression
AU741764B2 (en) Retroviral vector particles produced in a baculovirus expression system
EP1813676B1 (en) Retroviral vectors pseudotyped with influenza virus hemagglutinin for gene delivery
JP2003501070A (ja) 阻害性ＲＮＡ分子を決定するためのｉｎｖｉｖｏでの選択方法
US20030143205A1 (en) Alphavirus expression systems
GB2337520A (en) Retroviral delivery system
CA3171006A1 (en) Modified vectors for production of retrovirus
JP2003500061A (ja) 改善されたレトロウイルスの産生

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)